Glioblastoma / Brain Tumors Reagents

Home > Featured Products > Oncology Research > Glioblastoma / Brain Tumors

Glioblastoma (GBM) is the most aggressive primary brain tumor. Molecular classification — IDH status, EGFR amplification, MGMT methylation — guides prognosis and emerging therapeutic strategies. abinScience provides validated antibodies, recombinant proteins, and biosimilar-grade reference proteins for the targets listed below. RUO

Key Biomarkers & Targets

EGFR / EGFRvIII

ErbB1

EGFR amplified in ~60% of primary GBM; EGFRvIII is a tumor-specific neoantigen. 108 products. Validated: Blocking, ELISA, FC, IHC, SPR, WB.

Antibodies • Biosimilars • Proteins

IDH1 / IDH2

Isocitrate Dehydrogenase

IDH1 R132H defines lower-grade gliomas. Now therapeutic target (vorasidenib). 7 products. Validated: ELISA, IHC, WB.

Antibodies • Proteins

GFAP

Glial Fibrillary Acidic Protein

Canonical astrocyte/glial tumor marker. Serum biomarker for brain injury. 13 products. Validated: ELISA, IF, IHC, WB.

Antibodies • Proteins

PDGFRα/β

Platelet-Derived Growth Factor Receptor

PDGFRA amplification defines proneural GBM subtype. 46 products. Validated: ELISA, FC, IHC, WB.

Antibodies • Biosimilars • Proteins

VEGF

Angiogenesis

GBM is highly vascular; bevacizumab targets VEGF-A. 122 products. Validated: Blocking, ELISA, FC, IHC, SPR, WB.

Antibodies • Biosimilars • Proteins

PD-L1

CD274

Checkpoint target for GBM immunotherapy research. 130 products. Validated: Blocking, ELISA, FC, IF, IHC, WB.

Antibodies • Biosimilars • Proteins

Olig2

Oligodendrocyte TF

Glioma lineage marker for tumor classification. 3 products. Validated: ELISA, IHC, WB.

Antibodies • Proteins

TERT

Telomerase Reverse Transcriptase

TERT promoter mutation is a GBM diagnostic criterion. 10 products. Validated: ELISA.

Antibodies • Proteins

Why Researchers Choose abinScience

IHC-Validated AntibodiesAntibodies with IHC validation available for: EGFR, IDH1, GFAP, PDGFR, VEGF, PD-L1. See individual product pages for clone details and recommended dilutions.

Flow Cytometry ReadyFC-validated antibodies available for: EGFR, PDGFR, VEGF, PD-L1. Multiple conjugates (FITC, APC, PE, PerCP) offered for select clones.

Research-Grade BiosimilarsBiosimilar-grade reference proteins with ELISA and FACS validation for: EGFR, PDGFR, VEGF, PD-L1.

Original Manufacturer PricingDirect-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

IHC-based biomarker detection: We offer IHC-validated antibodies for EGFR, IDH1, GFAP, PDGFR, VEGF. See product pages for validated species and recommended dilutions.
Flow cytometry immunophenotyping: FC-validated antibodies available for EGFR, PDGFR, VEGF, PD-L1. Select clones offered in FITC, APC, PE, and PerCP conjugates.
Functional and blocking assays: Antibodies with blocking/neutralization validation available for: EGFR, VEGF, PD-L1.
Biosimilar comparability: Research-grade biosimilar proteins (ELISA/FACS/Functional assay validated) available for EGFR, PDGFR, VEGF, PD-L1.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

What PD-L1 reagents do you offer?

We offer 58 detection antibodies, 59 research-grade biosimilar proteins, and 13 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IF, IHC, WB. Available clones include: 22C3 (ELISA, FC, IHC, WB; APC, FITC, PE), Polyclonal (ELISA, IHC, WB; unconjugated), SP142 (ELISA, IHC, WB; unconjugated). Research-grade biosimilar proteins also available (e.g., Envafolimab, Pacmilimab, Cosibelimab).

What VEGF reagents do you offer?

We offer 66 detection antibodies, 39 research-grade biosimilar proteins, and 17 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IHC, SPR, WB. Available clones include: Polyclonal (ELISA, IHC, WB; unconjugated), 1A169 (ELISA, IHC, WB; unconjugated), YW64.3 (ELISA, FC; APC, FITC, PE). Research-grade biosimilar proteins also available (e.g., Vesencumab, Navicixizumab, Dilpacimab).

What EGFR / EGFRvIII reagents do you offer?

We offer 45 detection antibodies, 49 research-grade biosimilar proteins, and 14 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IHC, SPR, WB. Available clones include: SAA2220 (ELISA, FC, IHC, WB; APC, FITC, PE), Polyclonal (ELISA, IHC, WB; unconjugated), 11F8 (ELISA, FC, WB; APC, FITC, PE). Research-grade biosimilar proteins also available (e.g., Modotuximab, Tomuzotuximab, Depatuxizumab).

What PDGFRα/β reagents do you offer?

We offer 28 detection antibodies, 5 research-grade biosimilar proteins, and 13 recombinant proteins. Validated applications include: ELISA, FC, IHC, WB. Available clones include: Polyclonal (ELISA, IHC, WB; unconjugated), SAA0056 (FC; APC, FITC, PE), SAA0057 (FC; APC, FITC, PE). Research-grade biosimilar proteins also available (e.g., Tovetumab, Rinucumab, Olaratumab).

Can I get custom antibodies for novel targets?

Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.